Clinical trials: Resolution
Unspecified Disorder of Nose and Nasal Sinuses
Immediate Effect of Proponent-Nasal-Spray on Unspecific Discomfort in the Nose
Investigation of the immediate effect on subjective relief of symptoms by Proponent - Nasal - Spray after a one time administration (following a single dose administration in each nostril) in an open, not randomised, non-blinded…
- Trial name
- NCT03251066
- Testing
- Proponent Nasal Spray
- Where
- Switzerland
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- PRECLIN Biosystems AG
Resolution of Inflammation, Reduction of Cell Proliferation
Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).
The purpose of this biological study is to provide Dr. Samuel Fortin's laboratory with a continuous supply of blood mononuclear cells (PBMCs) so that he can pursue research on the potential beneficial effects of monoglyceride…
- Trial name
- PBMC (NCT05161702)
- Testing
- MAG-SPM treatment on isolated PBMC cells, Isolated PBMC cells without treatment.
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- SCF Pharma
Patients Having Undergone Unilateral Cataract Extraction and Implantation of a Monofocal
OPEN-LABEL, MULTI-CENTER, PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPHTHALMIC SOLUTION IN PATIENTS HAVING UNDERGONE CATARACT SURGERY WITH IMPLANTATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS (IOL)
To evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution, EGP-437®, using the EyeGate® II Drug Delivery System (EGDS) in patients having undergone cataract surgery with…
- Trial name
- NCT02571556
- Testing
- Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Contact Lens Wear
A Safety and Effectiveness Study of a New Multi-Purpose Contact Lens Care Solution
The objective of this study is to evaluate the safety and effectiveness of ASP-57 Multi-Purpose contact lens solution (Test) compared to ReNu® Multiplus Contact Lens Solution (Control) when used by habitual contact lens wearers…
- Trial name
- NCT03537248
- Testing
- ASP-57, ReNu® Multiplus
- Where
- 14 sites in United States
- Volunteers
- 315 people
- Sponsor
- Asepticys LLC
Meniere´s Disease
Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease
The purpose of this study is to evaluate the efficacy and safety of isosorbide oral solution compared with placebo in people with unilateral Meniere's disease.
- Trial name
- MD (NCT06765993)
- Testing
- Isosorbide oral solution
- Volunteers
- 234 people
- Sponsor
- Lunan Better Pharmaceutical Co., LTD.
Ocular Hypertension, Glaucoma
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the ocular and systemic safety of Netarsudil (AR-13324) Ophthalmic Solution, 0.02% q.d. and b.i.d. for 12 months compared to the active comparator Timolol Maleate Ophthalmic Solution, 0.5%.
- Trial name
- NCT02246764
- Testing
- AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Aerie Pharmaceuticals
Healthy Male Adults
A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -
The purposes of this study are to evaluate the safety and plasma pharmacokinetics of DE-117 ophthalmic solution (one drop once daily for 7 days) in healthy male adults.
- Trial name
- NCT02650063
- Testing
- DE-117
- Where
- Japan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Glioblastoma
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
The primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18…
- Trial name
- NCT05736406
- Testing
- 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2, 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2
- Where
- 2 sites in United States, France
- Volunteers
- 12 people
- Sponsor
- Hemerion Therapeutics
Pneumonia, Bacterial
A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia
This study is a randomized, open-label phase I study. The primary objective of this study is to assess the pharmacokinetic (PK) profile of ME1100 in subjects with mechanically ventilated bacterial pneumonia (MVBP).
- Trial name
- NCT02459158
- Testing
- ME1100 inhalation solution
- Where
- 14 sites in United States
- Volunteers
- 25 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Idiopathic Pulmonary Fibrosis
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05537025
- Testing
- ARO-MMP7 Inhalation Solution
- Where
- 19 sites in Denmark, Italy and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Glaucoma, Ocular Hypertension
A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
The purpose of the study is to examine how preservative free tafluprost ophthalmic solution (0.0015%) is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure.
- Trial name
- NCT02102750
- Testing
- Preservative free tafluprost opthalmic solution
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 17 people
- Sponsor
- Santen Oy
Cataract Extraction
Effect on Wound Healing of Vigamox Versus Cravit
The purpose of this study was to compare the effects of Vigamox and Cravit on corneal wound healing after cataract surgery.
- Trial name
- NCT00840580
- Testing
- Moxifloxacin 0.5% ophthalmic solution (Vigamox), Levofloxacin 0.5% ophthalmic solution (Cravit)
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate the tolerability and safety of RKI983 ophthalmic solution and explore the effect of the compound on intraocular pressure in subjects with ocular hypertension.
- Trial name
- NCT00515424
- Testing
- RKI983
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Novartis
Nasal Congestion, Common Cold
Post-market Clinical Follow-up Study of an Isotonic Saline Solution for the Relief of Nasal Congestion in Infants and Toddlers
The goal of this observational post-market clinical follow-up study is to evaluate the safety and performance of the CE-marked nasal spray for the relief of nasal congestion in infants and toddlers aged 6 to 48 months at day 5…
- Conditions
- Nasal Congestion, Common Cold, Allergic Rhinitis, Rhinosinusitis
- Trial name
- NASBY (NCT07257224)
- Testing
- Quinton Medical Nasal Health Baby®
- Where
- 2 sites in Spain
- Volunteers
- 83 people
- Sponsor
- Laboratoires Quinton International S.L.
Geographic Atrophy, Age-Related Macular Degeneration
Geographic Atrophy Treatment Evaluation
The purpose of this study was to evaluate the safety and efficacy of AL-8309B Ophthalmic Solution versus Vehicle administered as a topical ocular drop for the treatment for geographic atrophy (GA) secondary to age-related macular…
- Trial name
- GATE (NCT00890097)
- Testing
- AL-8309B Ophthalmic Solution, AL-8309B Vehicle
- Volunteers
- 772 people
- Sponsor
- Alcon Research
Arrhythmias, Cardiac
Artificial Intelligence (AI) Enabled, Cloud-based ECG Diagnostic Solution (ZBPro) Feasibility Testing
The proposed research is to address the accessibility and affordability of technology to capture symptomatic and asymptomatic cardiac events via Long-Term Continuous Electrocardiogram Monitoring (LTCM), and to provide physicians…
- Trial name
- NCT06013917
- Testing
- Cardiac Monitoring
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- ZBeats INC
Alopecia Areata, Alopecia Universalis
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT…
- Conditions
- Alopecia Areata, Alopecia Universalis, Alopecia Totalis
- Trial name
- NCT03759340
- Testing
- ATI 502 0.46% Topical Solution
- Where
- 20 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aclaris Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
The primary objective was to compare the bronchodilator efficacy of two doses (5 mcg and 10 mcg) of tiotropium inhalation solution delivered by the Respimat inhaler once daily to placebo and to ipratropium bromide MDI four times…
- Trial name
- NCT00240435
- Testing
- 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler, 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler
- Where
- 25 sites in United States, Canada
- Volunteers
- 491 people
- Sponsor
- Boehringer Ingelheim
ADME
Mass Balance Study of [14C]Xeruborbactam (QPX7728) in Healthy Adult Male Participants
This is a single-dose, phase 1 open-label study to determine the mass balance recovery and metabolic profiling and identification for intravenous (IV) administered [14C]xeruborbactam.
- Trial name
- NCT07083817
- Testing
- [14C]Xeruborbactam
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Qpex Biopharma, Inc.
Alopecia
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
Phase II clinical trial
- Trial name
- ELAN (NCT02919735)
- Testing
- CG 428 cutaneous solution
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Legacy Healthcare SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.